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Abstract
Question
Should patients with newly-diagnosed metastatic brain
tumors undergo stereotactic radiosurgery (SRS) compared
with other treatment modalities?
Target population
These recommendations apply to adults with newly diagnosed solid brain metastases amenable to SRS; lesions
amenable to SRS are typically defined as measuring less
than 3 cm in maximum diameter and producing minimal
(less than 1 cm of midline shift) mass effect.
Recommendations
SRS plus WBRT vs. WBRT alone
Level 1 Single-dose SRS along with WBRT leads to significantly longer patient survival compared with WBRT
alone for patients with single metastatic brain tumors who
have a KPS C 70.
Level 2 Single-dose SRS along with WBRT is superior in
terms of local tumor control and maintaining functional
status when compared to WBRT alone for patients with
1–4 metastatic brain tumors who have a KPS C 70.
Level 3 Single-dose SRS along with WBRT may lead to
significantly longer patient survival than WBRT alone for
patients with 2–3 metastatic brain tumors.
Level 4 There is class III evidence demonstrating that
single-dose SRS along with WBRT is superior to WBRT
alone for improving patient survival for patients with single
or multiple brain metastases and a KPS \ 70.
SRS plus WBRT vs. SRS alone

Level 2 Single-dose SRS alone may provide an equivalent
survival advantage for patients with brain metastases compared with WBRT ? single-dose SRS. There is conflicting
class I and II evidence regarding the risk of both local and
distant recurrence when SRS is used in isolation, and class I
evidence demonstrates a lower risk of distant recurrence with
WBRT; thus, regular careful surveillance is warranted for
patients treated with SRS alone in order to provide early
identification of local and distant recurrences so that salvage
therapy can be initiated at the soonest possible time.
Surgical Resection plus WBRT vs. SRS – WBRT
Level 2 Surgical resection plus WBRT, vs. SRS plus
WBRT, both represent effective treatment strategies,
resulting in relatively equal survival rates. SRS has not
been assessed from an evidence-based standpoint for larger
lesions ([3 cm) or for those causing significant mass effect
([1 cm midline shift). Level 3: Underpowered class I
evidence along with the preponderance of conflicting class
II evidence suggests that SRS alone may provide equivalent functional and survival outcomes compared with
resection ? WBRT for patients with single brain metastases, so long as ready detection of distant site failure and
salvage SRS are possible.
SRS alone vs. WBRT alone
Level 3 While both single-dose SRS and WBRT are
effective for treating patients with brain metastases, singledose SRS alone appears to be superior to WBRT alone for
patients with up to three metastatic brain tumors in terms of
patient survival advantage.
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A significant proportion of adults with cancer will develop
brain metastases. This number is increasing as advances
extend cancer patient survival leading to increasing riskyears for brain metastasis development. The precise incidence and epidemiology of metastatic brain tumors is
poorly studied and understood, however, it is estimated that
approximately 1.4 million Americans are diagnosed with
cancer every year [1] and up to 40% of these patients—
over a half million people annually—will go onto develop
one or more brain metastases [2]. Solid brain tumors represent 90–95% of brain metastases with meningeal
involvement accounting for the balance [3–5]. Approximately 37–50% of solid tumor patients present with single
brain metastases while roughly 50–63% have multiple
tumors at initial presentation [2, 6, 7]. Given that SRS can
treat more than one tumor per session, and that most
tumors are detected while small in size, the percentage of
patients that are potential candidates for SRS is quite large.
The outcome for patients with brain metastases is generally poor, with a median survival following WBRT alone

of only 3–4 months regardless of primary tumor histology
(small cell lung carcinoma (SCLC) excepted) [7–18].
Indeed, after WBRT, 50% of patients still succumb to their
brain tumor [14]. These results have driven efforts to
improve results by exploring modalities to improve quality
of life through better local control, as well as overall
survival.
For patients with single accessible brain metastases,
surgical resection followed by post-operative WBRT has
been compared to WBRT alone in three randomized controlled trials (RCT) [13, 14, 17].The evidence for this
combined treatment approach is reviewed in the WBRT
guideline paper of this series by Gaspar et al. [19].
Outcomes for patients with single solid metastatic brain
tumors amenable to either surgical resection or SRS have
been shown to be roughly equivalent for both local control
and overall patient survival [14, 15, 17, 20–26]. Open
surgery has the potential for better overall outcomes for
lesions [3 cm in diameter in locations amenable to
resection with acceptable risk, and better and/or faster
outcomes for smaller lesions causing symptomatic edema
or mass effect. On the other hand, SRS may result in
superior local control rates for radioresistant lesions (e.g.,
renal cell, melanoma, etc.), and may allow WBRT to be
deferred for subsequent salvage treatment without adverse
sequelae. The evidence for these conclusions is reviewed in
the surgical resection guideline paper in this series by
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Kalkanis et al. [27]. SRS has the ability to treat lesions that
may not be safely resectable.
Patients are generally considered candidates for SRS if
the tumor(s) in question is less than 10 cc in volume
(\3 cm average diameter) [20–22, 24–26]. The number of
tumors that can be effectively treated with SRS in a given
patient is an area still under study. SRS itself has
undergone recent scrutiny to better define its boundaries.
In 2006, the American Society for Therapeutic Radiology
and Oncology (ASTRO), the American Association of
Neurological Surgeons (AANS) and the Congress of
Neurological Surgeons (CNS) jointly agreed to define
SRS in a way that includes both traditional single dose
SRS, as well as multi-dose SRS up to five doses (2–5
doses) [28, 29].
The surgical resection guideline paper in this series
addresses the relative roles of surgical resection plus
WBRT vs. SRS ? WBRT for patients with single solid
brain metastases. This paper will briefly summarize those
findings but then expand the focus to explore patients with
multiple metastases. This paper will also explore the relative need for WBRT when SRS is utilized as a sole treatment modality, the relative role of WBRT if SRS is used to
augment surgical resection, as well as the relative role of
multi-dose SRS vs. single dose SRS.
The overall objectives of this paper are:
To systematically review the evidence available for the
following treatment comparisons for patients with newly
diagnosed brain metastases.
WBRT vs. WBRT ? SRS
SRS vs. WBRT ?SRS
WBRT vs. SRS
SRS ? WBRT vs. Resection ? WBRT
SRS vs. Resection ? WBRT
Other Comparisons
Multi-dose SRS vs. WBRT
Multi-dose SRS vs. Resection ? WBRT or local
radiotherapy (RT)
Resection ? WBRT vs. Resection ? SRS
Single dose SRS ± WBRT vs. Multi-dose SRS ?
WBRT

Methods
Search strategy
The following electronic databases were searched from
1990 to September 2008: MEDLINE, Embase, Cochrane Database of Systematic Reviews, Cochrane Controlled Trials Registry, Cochrane Database of Abstracts
of Reviews of Effects. A broad search strategy using a
combination of subheadings and text words was
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employed. The search strategy is documented in the
methodology paper for this guideline series by Robinson
et al. [30]. Reference lists of included studies were also
reviewed.
Eligibility criteria
•
•
•

•

Published in English.
Patients with newly diagnosed brain metastases.
Fully-published (i.e., not in abstract form) peerreviewed primary comparative studies. (These included
the following comparative study designs for primary
data collection: RCTs, non-randomized trials, cohort
studies, and case–control studies.
Study comparisons include one or more of the following (local RT = fractionated radiotherapy localized to
the tumor):
–
–
–
–
–
–

•

•

WBRT vs. WBRT ? SRS
SRS vs. WBRT ? SRS
SRS vs. WBRT
SRS ± WBRT or local RT vs. Resection ± WBRT
or local RT
SRS ± Resection vs. WBRT ± Resection
Single dose SRS ± WBRT vs. Multi-dose SRS ±
WBRT

Number of study participants with newly diagnosed
brain metastases C5 per study arm for at least two of
the study arms.
Baseline information on study participants is provided
by treatment group in studies evaluating interventions
exclusively in patients with newly diagnosed brain
metastases. For studies with mixed populations (i.e.,
includes participants with conditions other than newly
diagnosed brain metastases), baseline information is
provided for the intervention sub-groups of participants
with newly diagnosed brain metastases.

Study selection and quality assessment
Two independent reviewers evaluated citations using
a priori criteria for relevance and documented decisions in
standardized forms. Cases of disagreement were resolved
by a third reviewer. The same methodology was used for
full text screening of potentially relevant papers. Studies
which met the eligibility criteria were data extracted by one
reviewer and the extracted information was checked by a
second reviewer. The PEDro scale was used to rate the
quality of randomized trials [31, 32]. The quality of comparative studies using non-randomized designs was evaluated using eight items selected and modified from existing
scales.
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Evidence classification and recommendation levels
Both the quality of the evidence and the strength of the
recommendations were graded according to the AANS/
CNS criteria. These criteria are provided in the methodology paper to this guideline series.
Guideline development process
The AANS/CNS convened a multi-disciplinary panel of
clinical experts to develop a series of practice guidelines on
the management of brain metastases based on a systematic
review of the literature conducted in collaboration with
methodologists at the McMaster University Evidencebased Practice Center.
Scientific foundation
Overall 16,966 publications were screened. Fifty-six publications passed through the title and abstract screening to
the full text screening level. Ultimately, 32 publications (31
Fig. 1 Flow of studies to final
number of eligible studies

primary studies and one companion paper) met the eligibility criteria. Figure 1 outlines the flow of the studies
through the review process.
Whole brain radiotherapy alone versus whole brain
radiotherapy plus stereotactic radiosurgery
Two prospective RCTs (class I evidence) [25, 33] and one
retrospective cohort study with historical controls (class III
evidence) [34] evaluated WBRT alone vs. WBRT ? SRS
for the initial management of patients with solid metastatic
brain tumors. One prospective cohort study (class II evidence) evaluated WBRT alone vs. WBRT ? SRS for the
initial management of patients with solid metastatic brain
tumors in two arms of a three-arm study that also evaluated
SRS alone [35] (Table 1). One retrospective cohort study
(class II evidence) evaluated WBRT alone vs. WBRT ?
SRS as two of the arms in a four arm study that also
included SRS alone and surgery alone (Table 1) [36]. In all
five of these unique studies, only single-dose SRS was
evaluated, and the results cannot be assumed to apply to
2–5 dose SRS [28, 29].

Title and Abstract Screening
n=16,966
Excluded at Title and
Abstract
n=16,910
Full Text Screening
n=56
24 Excluded
No baseline patient data by treatment group…………... 13
No treatment comparison of interest……………………. 4
No extractable data....………………………………….... 2
Mixed population group (new and recurrent BM)…........ 1
Non-comparative study…………………………………. 2
Commentary/Narrative review…………………………..2
Eligible Studies
n=32

32 Included
WBRT vs. WBRT + SRS .……………………………....3
WBRT vs. SRS ……….………………………………...4
WBRT vs. SRS vs. WBRT + SRS ….…………………...1
SRS vs. WBRT + SRS ………………………………....11
[10 unique studies, 1 companion study]
SRS vs. surgery + WBRT ......…………………....……....3
SRS + WBRT vs. surgery + WBRT .…………………….4
Other …………………………………………. …………6
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Study design
Evidence class

Datta (2004)
[51]

WBRT vs. SRS

Sanghavi
(2001) [34]

Kondziolka
(1999) [25]

Andrews
(2004) [33]

Evidence class III

Retrospective cohort
study with
historical controls

Evidence class III

Retrospective cohort
study with
historical controls

Evidence class I

RCT

Evidence class I

RCT

WBRT vs. WBRT ? SRS

First author
(year)

G2: SRS ± WBRT
(n = 53) [12/53
(23%) had WBRT
prior to SRS]

G1: WBRT
(n = 67)

G2: WBRT ? SRS
(n = 502)

G1: WBRT
(n = 1200

G2: WBRT ? SRS
(n = 13)

G1: WBRT
(n = 14)

G2: WBRT ? SRS
(n = 164)

G1: WBRT
(n = 167)

Interventions

Table 1 Evidence table—summary of primary studies

BM

BM

2–4 BM

1–3 BM

Population

G2: 6 months (Survival curves:
log-rank; p = NS)

G1: 6 months

(Greenwood’s estimates;
p \ 0.05)

G2: RPA class III 8.7 months

G1: RPA class III 2.3 months

(Greenwood’s estimates;
p \ 0.05)

G2: RPA class II 10.3 months

G1: RPA class II 4.2 months

(Greenwood’s estimates;
p \ 0.05)

G2: RPA class I 16.1 months

G1: RPA class I 7.1 months

G2: 11 months (Survival curves:
log-rank; p = NS)

G1: 7.5 months

G2: 6.5 months (Survival curves:
log-rank; p = 0.0393)

Median survival for single BM pts:
G1: 4.9 months

G2: 5.7 months (Survival curves:
log-rank; p = NS

G1: 6.5 months

Median survival overall:

Median survival

NR

NR

G2: 8%

G1: 100%

1 yr local failure rate:

G2: 82% (p = 0.01)

G1: 71%

Central review assessed
1 yr local control:

# Pts with recurrence/
Progressionc

NR

NR

G2: 34 months (Test
unclear; p = 0.002)

G1: 5 months

Overall in brain:

G2: 36 months (LR
curves: log-rank;
p = 0.0016

G1: 6 months

At original site:

(BR curves: log-rank;
p = NS)

Overall in
brain:Median: NR

Median: NR (LR
curves: log-rank;
p = 0.0132)

At original site:

Median time to
recurrence/progression

J Neurooncol (2010) 96:45–68
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Rades (2007)
[50]

Retrospective cohort
study

Lee (2008) [49]

G1: WBRT
(n = 91)
G2: SRS (n = 95)

Evidence class II

G2: SRS (n = 7)

G1: WBRT (n = 8)

G2: WBRT
(n = 138)

G1: SRS (n = 117)

Interventions

Retrospective cohort
study

Evidence class II

Retrospective cohort
study with
historical controls
Evidence class III

Study design
Evidence class

Kocher (2004)
[52]

First author
(year)

Table 1 continued

BM

BM from
epithelial
ovarian
cancer

1–3BM

Population

G2: 13 months (Survival curves:
log-rank; p = 0.045)

G1: 7 months

G2: 29 months (Survival curves;
log-rank: p = 0.0061)

G1: 6 months

G2: RPA class III 2.5 months
(Test not reported; p = NS)

(Test not reported; p \ 0.04)
G1: RPA class III 4.2 months

G2: RPA class II 4.1 months

G1: RPA class II 5.9 months

G2: RPA class I 4.7 months (Test
not reported; p \ 0.0001)

G1: RPA class I 25.4 months

Median survival

G2: 49%

G1: 23%

1 yr overall brain
control rate:

G2: 61%

G1: 66%

1 year distant brain
control rate:

G2: 64%

G1: 26%

1 year local brain
control rate:

(BR curves: log-rank;
p = 0.005)

Median: Not reported
by treatment group

Anywhere in brain:

(DR curves: log-rank;
p = NS)

Median: Not reported
by treatment group

(LR curves: log-rank;
p \ 0.001)
At distant brain sites:

Median: Not reported
by treatment group

At original site:

NR

NR

NR by treatment groups

NR

Median time to
recurrence/progression

# Pts with recurrence/
Progressionc

50
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Study design
Evidence class

G2: SRS (n = 23)

Evidence class II

Aoyama (2006,
2007) [38, 39]

RCT
Evidence class I

G1: SRS (n = 67)
G2: WBRT ? SRS
(n = 65)

G3: SRS ? WBRT
(n = 18)

G1: WBRT
(n = 19)

Interventions

Prospective cohort
study

SRS vs. WBRT ? SRS

Li (2000) [35]

WBRT vs. SRS vs. WBRT ? SRS

First author
(year)

Table 1 continued

1–4BM

Lung cancer
BM

Population

G1: 8.0 months
G2: 7.5 months (Survival curves:
log-rank; p = NS)

Survival curves G2 vs. G3: logrank; p = NS

Survival curves 3 groups: logrank; p \ 0.0001

G3: 10.6 months

G2: 9.3 months

G1: 5.7 months

Median survival

Overall in brain:
Median: NR (BR
curves: log-rank;
p \ 0.001)

G2: 89%
1 year DR rate:

G2: 47%

G1: 76%

1 yr BR rate:

G2: 42%

G1: 64%

G1: 73%

At distant brain site:
Median: NR(DR curves:
log-rank; p = 0.003)

G3: 8.6 months (DR
curves of 3 groups:
log-rank; p = 0.0000)
(DR curves G2 vs. G3:
log-rank; p = 0.0392)

G2: 6.7 months

G1: 4.1 months

At distant sites in brain:

(LR curves G2 vs. G3:
log-rank; p = NS)

G3: 8.6 months (LR
curves of 3 groups:
log-rank; p = 0.0000)

G2: 6.9 months

G1: 4.0 months

At original site:

Median time to
recurrence/progression

1 year local control rate
(by lesion):

progression 0/18 (3
groups: p = 0.004)
(G2 vs. G3: p = NS)

no change 2/18 (11%)

G3: CR or PR 16/18
(89%)

progression 0/23

no change 3/23 (13%)

G2: CR or PR 20/23
(87%)

progression 4/29 (14%)

no change 11/29 (38%)

G1: CR or PR 14/29
(48%)

# of pts with the
following tumor
response:

# Pts with recurrence/
Progressionc

J Neurooncol (2010) 96:45–68
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Hoffman
(2001) [42]

Combs (2004)
[41]

Chidel (2000)
[40]

First author
(year)

Table 1 continued

Evidence class II

Retrospective cohort
study

Evidence class II

Retrospective cohort
study

Evidence class II

Retrospective cohort
study

Study design
Evidence class

G3: SRS for
recurrent BM
(n = 53)

G2: WBRT ? SRS
(n = 19)

G1: SRS (n = 41)

G3: SRS for
recurrence
(n = 39)

G2: WBRT ? SRS
(n = 13)

G1: SRS (n = 10)

G2: WBRT ? SRS
(n = 57)

G1: SRS (n = 78)

Interventions

Lung cancer
BM

Beast cancer
BM

BM

Population

G3: 10.0 months (G1 vs. G2 cox
univariate; p = NS)

G2: 14.5 months

G1: 13.9 months

G3:19 months (G1 vs. G2 survival
curves log-rank: p = 0.036)

G2: 6 months

G1: 9 months

G2: 6.4 months (Survival curves:
log-rank; p = NS)

G1: 10.5 months

Median survival

Overall in brain:
G1: 6.9 months
G2: 15.0 months
G3: 5.8 months (G1 vs. G2 BR
curves: log-rank; 0.002)

G1: 13%
G2: 67%
G3: 27%

G3: 16.5 months (G1 vs. G2
DR curves: log-rank;
p = 0.015)

G2: Not reached

G1: 8.0 months

G3: 9.2 months (G1 vs. G2 LR
curves: log-rank; p = NS)
At distant brain site:

G2: Not reached

G1: 22.2 months

At original site:

G3: 7 months (G1 vs. G2 DR
curves: log-rank; p = NS)

G2: 4.0 months

G1: 6.5 months

G3: 9 months (G1 vs. G2 LR
curves: log-rank; p = NS)
At distant brain site:

G2: 4.0 months

G1: 6.5 months

At original site:

G2: 35.1 months (BR curves:
log-rank; p = 0.027)

G1: 9.2 months

Overall in brain:

Median: NR (DR curves: logrank; p = NS)

At distant brain site:

Median: NR (LR curves: logrank; p = 0.034)

At original site:

Median time to
recurrence/progression

1 year freedom from
BR:

G3: 55%

G2: 78%

G1: 33%

G3: 36%
1 year freedom from
DR:

G2: 88%

G1: 62%

1 year freedom from
LR:

NR

G2: 60%

G1: 34%

G2: 74%
2 year freedom from
BR rate:

2 year freedom from
DR rate: G1: 48%

G2: 80%

G1: 52%

2 year local control rate:

# Pts with recurrence/
Progressionc
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Sneed (2002)
[47]

Sneed (1999)
[46]

Pirzkall (1998)
[45]

Noel (2003)
[44]

Jawahar (2002)
[43]

First author
(year)

Table 1 continued

Evidence class II

Retrospective cohort
study

Evidence class II

Retrospective cohort
study

Evidence class II

Retrospective cohort
study

Evidence class II

Retrospective cohort
study

Evidence class II

Retrospective cohort
study

Study design
Evidence class

G2: WBRT ? SRS
(n = 301)

G1: SRS (n = 268)

G2: WBRT ? SRS
(n = 43)

G1: SRS (n = 62)

G2: WBRT ? SRS
(n = 78)

G1: SRS (n = 158)

G3: SRS for
recurrence BM
(n = 36)

G2: WBRT ? SRS
(n = 22)

G1: SRS (n = 34)

G2: SRS ? WBRT
(n = 18)

G1: SRS (n = 43)

Interventions

BM

BM

1–3 BM

BM

BM

Population

G2: 8.6 months (Univariate Cox;
p = NS)

G1: 8.2 months

G2: 11.1 months (Survival curves:
log-rank; p = NS)

G1: 11.3 months

G2: 30% (Survival curves: logrank; p = NS)

G1: 19%

1 year survival rates:

Median: NR by treatment group

G3: 8 months (G1 vs. G2 survival
curves: log-rank; p = NS)

G2: 14 months

G1: 7 months

Median: NR by treatment group
(Survival curves: log-rank;
p = NS)

Median survival

NR

G2: 16/43 (37%)

G1: 36/62 (58%)

Overall in brain:

G2: 12/43 (28%)

G1: 31/62 (50%)

At distant brain sites

G1: 13/62 (21%)
G2: 7/43 (16%)

At original site:

NR

G2: 15.9 months (BR curves:
log-rank; p = 0.008)

G1: 8.3 months

Overall in brain:

G2: 16.8 months (DR curves:
log-rank; p = 0.03)

G1: 8.5 months

At distant brain sites:

G1: 21.0 months
G2: Not reached (LR curves:
log-rank; p = NS)

At original site:

G2: 5.4 months (p = NR)

G1: 4.3 months

At distant brain site:

Median time: NR (LR curves:
log-rank; p = NS)
G1: 89%
G2: 92%

At original site:

G3: Not reached

G2: 24 months (G1 vs. G2 BR
curves: NR)

G1: 13 months

Overall in brain:

NR

Median time to
recurrence/progression

1 year local control rate:

G3: 86%

G2: 94%

G1: 78%

1 year local control rate:

Reported no significant
difference between
groups [data: NR]

Distant tumor
recurrence:

Reported no significant
difference between
groups [data: NR]

Local tumor control:

# Pts with recurrence/
Progressionc

J Neurooncol (2010) 96:45–68
53

123

123

Evidence class II

Retrospective cohort
study

Study design
Evidence class

Rades (2007)
[59]

Muacevic
(1999) [58]

Muacevic
(2008) [57]

Evidence class II

Retrospective cohort
study

Evidence class II

Retrospective cohort
study

Evidence class I

RCT

SRS vs. Surgery ?WBRT

Varlotto (2005)
[48]

First author
(year)

Table 1 continued

G2:
Surgery ? WBRT
(n = 112)

G1: SRS (n = 94)

G2:
Surgery ? WBRT
(n = 52)

G1: SRS (n = 56)

G1:
Surgery ? WBRT
(n = 33)
G2: SRS (n = 31)

G2: WBRT ? SRS
(n = 70)

G1: SRS (n = 40)

Interventions

Single BM

Single BM

Single BM

Pts surviving
[1 year
after SRS
for BM

Population

G1: 54%
G2: 38% (Survival curves: logrank; p = NS)

1 year survival rate:

Median survival: NR

G2: 68 weeks (Survival curves:
log-rank; p = NS)

G1: 35 weeks

G2: 10.3 months (Survival curves:
log-rank; p = NS)

G1: 9.5 months

Median: NR by group (Survival
curves: log-rank; p = NS)

Median survival

Median: NR (BR curves: logrank; p = NS)
1 year freedom from
BR rate:
G2: 44%

G1: 49%

Overall in brain:

Median: NR (LR curves: logrank; p = NS)

At original site:

At distant site: NR

G1: Median not reached
G2: Median not reached (LR
curves: log-rank; p = NS)

At original site:

Median time to distant
recurrence in brain: Not
reported (DR curves: logrank; p \ 0.05)

G2: 56%

G1: 64%

1 year freedom from LR
rate:

G2: 90% (p = 0.0025)

G1: 68%

1 year freedom from
DR rate:

G2: 75%

G1: 83%

1 year freedom from LR
rate:

G2: 26%

G1: 3%

1 year distant
recurrence/
progression rates:

G2: 97%

1 year freedom from
local recurrence/
progression rates:
G1: 82%

G2: 21%
Median time to local
recurrence in brain: Not
reported (LR curves: logrank; p = NS)

Median: NR (DR curves: logrank; p = NS)

G1: 26%

At distant brain sites:

1 year distant
recurrence rates:

Median: NR (LR curves: logrank; p = 0.03)

At original site:

Median time to
recurrence/progression

G2: 93%

G1: 84%

1 year local control (by
lesion):

# Pts with recurrence/
Progressionc
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Study design
Evidence class

De Salles
(1993) [62]

Other

Schoggl (2000)
[56]

O’Neill (2003)
[55]

Garell (1999)
[54]

G1: SRS ± WBRT
(n = 19)
G2: SFR ± WBRT
(n = 7)

Evidence class II

G2: SRS ? WBRT
(n = 67)

Retrospective cohort
study

Evidence class II

G1:
Surgery ? WBRT
(n = 66)

G2: SRSa ± WBRT
(n = 23)

Evidence class II

Retrospective cohort
study

G1: Surgerya ±
WBRT (n = 74)

G2: SRS ? WBRT
(n = 8)

G1:
Surgery ? WBRT
(n = 37)

G2: SRS ± WBRTa
(n = 31)

G1: Surgery ±
WBRTa(n = 62)
[matched to G2]

Interventions

Retrospective cohort
study

Evidence class II

Retrospective cohort
study

Evidence class II

SRS ? WBRT vs. Surgery ?WBRT
Bindal (1996)
Retrospective cohort
[53]
study

First author
(year)

Table 1 continued

BM

Single BM

Single BM

Single BM

Single BM

Population

G1: 11/64 (17%)
G2: 0/21 (p = NR)
Overall in brain:

G2: 56% (Survival curves: logrank; p = NS)

G2: 7 months (p-value: NR)

G2: NR

G1: 4/19 (21%)
G1: 8 months

At distant sites in brain:
Average survival:

NR

G2: 4.4 months (DR curves:
test unclearb p = NS)

G2: 7/67 (10%)
(p = NR)
Median: NR

G1: 3.7 months

G1: 10/66 (15%)

G1: 3.9 months

At original site:
G2: 4.9 months (LR curves:
test unclearb p \ 0.05)
At distant brain sites:

G1: 11/66 (17%)

NR

NR

G2: Median not reached (DR
curves: log-rank; p = NS)

G1: Median not reached

At distant brain sites:

G2: 6 months (LR curves: logrank; p = 0.0001)

G1: Median not reached

At original site:

Median time to
recurrence/progression

G2: 3/67 (5%)
(p = NR)
At distant brain sites:

At original site:

G1: 9 months
G2: 12 months (Survival curves:
test unclearb; p = NS)

G2: 6/21(29%)
(p = NR)

G1: 19/64 (30%)

At original site:

1 year survival rate:
G1: 62%

NR

G2: 69%

1 year freedom from
DR rate:
G1: 75%

G2 poorer than G1
[Data: NR]

1 year freedom from LR
rate:

# Pts with recurrence/
Progressionc

Median survival: NR

G1: 8 months
G2: 12.5 months (Survival
curves:log-rank; p = NS)

G2: 7.5 months (Survival
curves:log-rank; p = 0.0018)

G1: 16.4 months

Median survival
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Retrospective cohort
study
Evidence class II

Retrospective cohort
study

Serizawa
(2000) [61]

Shinoura
(2002) [60]

Evidence class II

Retrospective cohort
study with
historical controls
Evidence class III

Evidence class II

Retrospective cohort
study

Study design
Evidence class

Lindvall
(2005) [63]

Ikushima
(2000) [64]

First author
(year)

Table 1 continued

G2: Surgery ? RT
(n = 35)
[RT = WBRT or
local]

G1: SRS (n = 28)

G2: SRS ± surgical
resection (n = 62)

G1:
WBRT ± surgical
resection (n = 34)

G2: WBRT ? SRS
or SFR (n = 14)

G1: SFR (n = 47)

G3: RT (n = 14)
[RT = WBRT or
local]

G2: Surgery ? RT
(n = 11)

G1 : SFR (n = 10)

Interventions

BM

NSCLC BM

BM

G1: 25.6 months

RCC BM

G2: 34.4 months (Survival curves:
log-rank; p \ 0.0001)

G1: 8.2 months

G2: 377 days (Survival curves:
log-rank: p = 0.0158)

G1: 199 days

G2: 5.0 months(Survival curves:
log-rank; p = NS)

G1: 5.0 months

G3: 4.3 months (Univariate
analysisd:G1 vs. G2 ? G3:
p = 0.05)

G2: 18.7 months

Median survival

Population

G1: 16/52 (31%)
G2:14/46 (30%)
(p = NR)

# lesions that recurred at
original site:

G2: 94.8%

1 year tumor control
rates:
G1: NR

G2: 0/11 (p = 0.0005)

G1: 8/32 (25%)

# of pts with recurrence
at distant sites:

G2: stable 11/11 (100%)
progression 0/11
(p = NS)

Local response (by
lesion) in the pts with
available data:
G1: stable 37/44 (84%)
progression 7/44
(16%)

G3: NR

G2: 88%

G1: 90%

1 year local control rate:

# Pts with recurrence/
Progressionc

G1: 7.2 months
G2: 25 months (LR curves: logrank; p = 0.0199)

Mean time to recurrence at
original site:

G2: 422 days (DR curves: logrank; p = NS)

G1: 539 days

At distant sites in brain:

NR

Median: NR (LR curves: log-rank;
p = NS)

At original site:

Median time to
recurrence/progression
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d

Either log-rank or Wilcoxon test

WBRT use similar at baseline in both groups

Number of pts with recurrence/progression of brain metastases, unless otherwise specified
Univariate analysis using Cox proportional hazard model
c

b

a

BM Brain metastases, BR Brain recurrence (local ? distant), CR Complete response, DR Distant recurrence in brain, G1 Group 1, G2 Group 2, G3 Group 3, G4 Group 4, LR Local recurrence
at original site in brain, NSCLC Non-small cell lung cancer, NR Not reported, NS Not significant, PR Partial response, Pts Patients, RCC Renal cell carcinoma, RCT Randomized control trial,
RPA Recursive partitioning analysis, RT Radiotherapy, SFR Stereotactic fractionated radiotherapy, SRS Stereotactic radiosurgery, WBRT Whole-brain radiation therapy
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G4: 96% (p = NR)

G3: 93%

G2: 88%

G4: 91.0 weeks (Survival curves:
log-rank; p \ 0.00001)
G4: SRS ? WBRT

G1: 89%
G3: 67.0 weeks
G3: SRS
Evidence class II

NR
Local tumor control at
1 month:
G1: 43.0 weeks

G2: 37.0 weeks
G2: WBRT

Wang (2002)
[36]

Retrospective cohort
study

G1: Surgery

BM

Median time to
recurrence/progression
Median survival
First author
(year)

Table 1 continued

Study design
Evidence class

Interventions

Population

# Pts with recurrence/
Progressionc
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The first RCT is a Radiation Therapy Oncology Group
(RTOG) multi-center trial led by Andrews et al., published
in 2004 [33]. The trial randomized adults with a Karnofsky
performance status (KPS) C 70 with 1–3 solid brain
metastases with a maximum diameter of 4 cm for the
largest and B3 cm for the remainder. Patients were stratified by number of metastases and extent of extra-cranial
disease. WBRT and SRS doses were standard. Overall
follow-up was a median of 12 months. Patient groups were
well matched for sex, age (19–90 years), histology, KPS,
and mini-mental status exam (MMSE) score. There were
164 patients in the WBRT ? SRS arm (of which 31/164
(19%) did not receive their planned SRS) and 167 patients
in the WBRT alone arm (of which 28/167 (17%) received
salvage SRS). The primary endpoint was median survival.
Secondary endpoints included tumor control at 1 year, KPS
and MMSE at 6 months and cause of death (neurologic vs.
non-neurologic). This trial can be criticized for a large
bilateral crossover rate in an intent-to-treat model, no follow-up neuroimaging review on 43% of patients, and
inclusion of tumors[3 cm diameter which are known to be
less favorable for SRS but were included in the original
RTOG 90-05 trial and were included for that reason (refer
to the surgical resection guideline paper by Kalkanis et al.
[27]. Nevertheless, this trial demonstrated significantly
better survival for patients with single metastatic tumors
(p = 0.01), superior local control for patients with 1–3
metastatic brain tumors (p = 0.01), and improved KPS for
patients with 1–3 metastatic brain tumors in the WBRT ?
SRS arm. The last two conclusions were secondary endpoints assessed with post hoc analysis and thus, are not as
strong as the single tumor survival conclusion. There was
no significant difference between groups in median survival for patients with 2–3 brain tumors, MMSE at
6 months, incidence of neurologic cause of death, or
adverse therapeutic events [33]. However, because of the
large follow-up loss in this study, no conclusion can be
assured.
The second RCT is a single institution study from the
University of Pittsburgh led by Kondziolka et al., published in 1999 [25]. The trial randomized adults with a
KPS C 70 with 2–4 solid metastatic brain tumors, each
B2.5 cm in mean diameter. WBRT and SRS doses were
standard. Overall follow-up was not reported. Patient
groups were well matched for sex, age (33–77 years),
histology, number of brain tumors, KPS score, and extent
of systemic disease. There were 14 patients in the WBRT
arm and 13 in the WBRT ? SRS arm. All patients completed the treatment in their intent-to-treat arm. Since the
primary endpoint was imaging-defined local control, no
patient received salvage SRS until they were censored for
analysis. Secondary endpoints included median survival,
and time to recurrence/progression at the original tumor
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sites. The study was stopped at the 60% accrual point due
to an overwhelmingly positive tumor control difference at
interim analysis. This trial demonstrated significantly better
local control rates measured in terms of local failure at
1 year (8 vs. 100%) and median time to recurrence/progression at original site (36 vs. 6 months) for patients in the
WBRT ? SRS arm. Since the study was stopped at 60%
accrual, its statistical power to assess differences in median
survival was limited. Despite a large trend of 11 vs.
7.5 months favoring WBRT ? SRS, this result did not
achieve statistical significance due to the relatively low
number of patients. Functional performance outcome,
cause of death, and incidence of adverse events were not
reported [25].
In the three arm prospective cohort study by Li et al.
[35] recruitment was restricted to patients with both small
cell- and non-small-cell lung cancer (NSCLC) and single
brain metastases B4.5 cm diameter in adults with a
KPS C 60, two of the three arms were WBRT (n = 19) vs.
WBRT ? SRS (n = 18). Groups were similar in terms of
sex, age, histology, extent of extracranial disease, and KPS
score. WBRT doses and SRS doses were standard. The
median survival advantage for WBRT ? SRS was highly
significant (p \ 0.0001) as was the advantage for local
tumor control (p = 0.004) and median time to progression
for the treated tumor (p \ 0.00001).
The four arm retrospective cohort study by Wang et al.
[36] evaluated adult patients with 1–6 metastases of varying histologies, each \4 cm in diameter, and a KPS of 40–
90; two of the four arms were WBRT alone (n = 120) vs.
WBRT ? SRS (n = 83). Groups were similar in terms of
sex and age. Primary histology, KPS score, and extent of
systemic disease were not reported by treatment group. The
WBRT ? SRS had significantly more patients with multiple brain tumors (50/83) than the WBRT alone arm
(34/120). WBRT doses and SRS doses were standard.
While 1 month local tumor control rates were similar
between groups (95.6 vs. 88.3%), median survival significantly favored the WBRT ? SRS group (91 vs. 37 weeks).
Sanghavi et al. [34] performed a large retrospective
cohort trial (n = 502) of patients with varying histologies
with historical controls based on recursive partitioning
analysis (RPA) [37] of a database of patients from RTOG
trials (n = 1,200) where patients received WBRT alone.
Groups were stratified by RPA class. Groups were similar in
age, and extent of extracranial disease. The WBRT group
had slightly lower KPS scores, while the WBRT ? SRS
group had a greater percentage of radioresistant histologies
(e.g., melanoma). They found statistically significant
improvements in survival for patients in all three RPA
classes, suggesting a survival benefit for SRS ? WBRT
even in patients with [1 metastatic brain tumor, the presence of systemic disease, and low KPS score.
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Stereotactic radiosurgery alone versus whole brain
radiotherapy plus stereotactic radiosurgery
One prospective RCT (class I evidence) with a companion
paper [38, 39], and nine retrospective cohort studies (class
II evidence) [40–48] evaluated SRS alone vs. WBRT ?
SRS for the initial management of patients with solid
metastatic brain tumors. One prospective cohort study
(class II evidence) evaluated SRS alone vs. WBRT ? SRS
for the initial management of patients with solid metastatic
brain tumors in two arms of a three-arm study that also
evaluated WBRT alone [35] (Table 1). One retrospective
cohort study (class II evidence) evaluated SRS alone vs.
WBRT ? SRS as two of the arms in a four arm study that
also included WBRT alone and surgery alone (Table 1)
[36]. In all 12 of these unique studies, only single-dose
SRS was evaluated, and the results cannot be assumed to
apply to 2–5 dose SRS [28, 29].
The RCT is a multi-institutional study from Japan led by
Aoyama et al., published in 2006 [38, 39]. The trial randomized adults with a KPS C 70 with 1–4 solid brain
metastases with a maximum diameter of B3 cm. Follow-up
was 20.7 months for the SRS arm and 30.5 months for the
WBRT ? SRS arm. Isolated WBRT and SRS alone doses
were standard, however, the SRS dose was reduced by 30%
in the WBRT ? SRS arm relative to the SRS alone arm.
Patient groups were similar in terms of sex, age, histology,
number of tumors, extent, and stability of extracranial
disease, primary tumor status, KPS score, and MMSE
score. There were 67 patients in the SRS alone arm (of
which 2/67 (3%) did not receive SRS, and 11/67 (16%)
received WBRT as a salvage therapy) and 65 in the
WBRT ? SRS arm (of which 6/65 (9%) did not receive
SRS, 2/65 (3%) did not receive WBRT, and 10/65 (15%)
received additional salvage SRS). The primary endpoint
was median survival. Secondary endpoints included 1 year
tumor control rate, 1 year recurrence rate at untreated sites,
neurologic cause of death, 1 year KPS score, 1 year
MMSE score, and adverse event rate. This trial can be
criticized for a large bilateral crossover rate in an intent-totreat model. Results revealed no significant difference
between study groups for median survival (8.0 vs.
7.5 months), 1 year local control rate (72.5 vs. 88.7%),
neurologic cause of death, 1 year KPS score, MMSE score,
or acute or late neurotoxicity. However, the 1 year chance
of recurrence locally (27.5 vs. 11.3%), at a distant site
(63.7 vs. 41.5%), or anywhere in the brain (76.4 vs. 46.8%)
was significantly greater for the SRS alone arm than the
WBRT ? SRS arm, as was the chance of requiring additional salvage therapy in the form of either SRS or WBRT
(43.3 vs. 15.4%). In a second, secondary endpoint analysis
publication from the same study looking at the 70% subset
of patients with initial and follow-up MMSE examinations,
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and then restricting analysis still further to the 62% of
patients with pre-treatment MMSE scores of C27 or who
improved on follow-up to MMSE scores C27, the addition
of up-front WBRT significantly increased the time to
MMSE deterioration, which was often due to distant tumor
recurrence [39].
In the three arm prospective cohort study by Li et al.
[35] recruitment was restricted to patients with both SCLC
and NSCLC, and single brain metastases B4.5 cm diameter
in adults with a KPS C 60; two of the three arms were SRS
(n = 23) vs. WBRT ? SRS (n = 18). Groups were similar
in terms of sex, age, histology, extent of extracranial disease, and KPS score. WBRT doses and SRS doses were
standard. There was no significant difference between the
two groups in terms of median survival (9.3 vs.
10.6 months) or in terms of recurrence/progression at the
treated site. Distant brain recurrence was not assessed.
Of the 10 retrospective cohort studies addressing this
comparison in patients with both single and multiple brain
metastases of varying histologies, nine are direct comparisons of SRS alone vs. WBRT ? SRS [40–48] and one is a
four arm retrospective cohort study with SRS and
WBRT ? SRS as two of the four comparison arms [36].
Of these 10 studies, eight show no significant difference in
median survival between both treatment options with ranges for median survival of 7–13.9 months and 6.4–14.9
months, respectively [40, 42–48]. One study of patients
with breast cancer brain metastases showed improved
median survival of 9 vs. 6 months favoring SRS alone [41],
and another studying tumors of varying histology showed
improved median survival of 91 vs. 67 weeks favoring
WBRT ? SRS [36]. Of the 10 studies, only one (which
studied only patients who had survived [1 year since
treatment) revealed a statistically significant increase in
local recurrence rate or reduced time to local recurrence
[48]. However, four revealed either increased distant brain
or overall brain recurrence rates and/or reduced time to
distant brain or overall brain recurrence [40, 42, 44, 45].
On the other hand, the study of patients who had survived
[1 year since treatment suggested that while the median
time to local recurrence/progression was significantly
increased with SRS alone, the median time to distant
recurrence was not significantly different between the two
arms [48].
Stereotactic radiosurgery alone versus whole brain
radiotherapy alone
No RCTs were identified that met the eligibility criteria
for this treatment comparison. One prospective cohort
study (class II evidence) evaluated SRS alone vs. WBRT
alone for the initial management of patients with solid
metastatic brain tumors in two arms of a three-arm study

59

that also evaluated WBRT ? SRS [35]. There were two
retrospective cohort studies with concomitant control
groups (class II evidence) that compared SRS alone vs.
WBRT alone (Table 1) [49, 50]. There were two retrospective cohort studies with historical controls (class III
evidence) that compared SRS alone vs. WBRT alone
(Table 1) [51, 52]. One retrospective cohort study (class
II evidence) evaluated SRS alone vs. WBRT alone as two
of the arms in a four arm study that also included
WBRT ? SRS and surgery alone (Table 1) [36]. In all of
these unique studies, only single-dose SRS was evaluated,
and the results cannot be assumed to apply to 2–5 dose
SRS [28, 29].
The three arm prospective cohort study by Li et al.
(2000) [35] evaluated adult patients with both SCLC and
NSCLC, and single brain metastases B4.5 cm diameter in
adults with a KPS C 60, two of the three arms were SRS
alone (n = 23) vs. WBRT alone (n = 19). Groups were
similar in terms of sex, age, histology, extent of extracranial disease, and KPS score. WBRT doses and SRS doses
were standard. The SRS alone arm had significantly longer
median survival (9.3 vs. 5.7 months), neuroimaging tumor
response (complete or partial response 87 vs. 38%, and
progression 0 vs. 14%), and median time to progression
(6.9 vs. 4.0 months). Distant brain recurrence was not
assessed.
In the small retrospective cohort study by Lee et al. [49]
recruitment was restricted to patients with 1–12 non-germ
cell epithelial ovarian cancer brain metastases; 15 patients
were treated with either SRS alone (n = 7) or WBRT alone
(n = 8). Groups were poorly analyzed in terms of potentially relevant intergroup differences and SRS and WBRT
dosing parameter was not provided. Despite these issues,
the authors reported a significantly improved median survival outcome for the SRS arm (29 vs. 6 months for WBRT
alone).
In the large retrospective cohort study by Rades et al.
[50] 186 patients with 1–3 brain metastases of varying
histologies B4 cm diameter received either WBRT alone
(n = 91) or SRS alone (n = 95). Groups were well
matched for sex, age, RPA class, number of metastases,
extent of extracranial disease, baseline functional performance, and histology. Median survival was significantly
longer for the SRS alone group (13 vs. 7 months for
WBRT alone). One-year local and overall brain control
rates were likewise significantly better for the SRS alone
arm (64 vs. 26% and 49 vs. 23%, respectively). Distant
brain control rates were similar for both groups (66%
WBRT alone vs. 61% SRS alone). Toxicity rates were
similar for both groups.
The four arm retrospective cohort study by Wang et al.
[36] evaluated adult patients with one or more brain
metastases of varying histologies, each \4 cm in diameter
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and a KPS [ 50. Two of the four arms were SRS alone
(n = 130) vs. WBRT alone (n = 120). Groups were similar in terms of sex and age. Primary histology, KPS score,
and extent of systemic disease were not reported by treatment group. The SRS treatment group had more patients
with multiple brain tumors (50/83) than the WBRT alone
arm (34/120). WBRT doses and SRS doses were standard.
While 1 month local tumor control rates were similar
between groups (93.3 vs. 88.3%), median survival significantly favored the SRS group (67 vs. 37 weeks).
Kocher et al. [52] performed a retrospective cohort trial
of SRS (n = 117) compared against 138 WBRT historic
control patients treated 1–20 years previously at the same
institution for brain metastases patients with multiple
histologies and B3 tumors. Groups were similar in terms of
sex and age and were stratified according to RPA classification which accounted for extent of extra-cranial disease,
number of tumors, and functional status [37]. The SRS
alone arm had more melanoma patients (27 vs. 6%).
WBRT and SRS doses were standard. They reported
significantly better results with SRS alone for RPA class I
(25.4 vs. 4.7 months) and RPA class II (5.9 vs. 4.1
months). Difference in results for RPA class III (4.2 vs.
2.5 months) did not reach statistical significance.
Datta et al. [51] performed a retrospective cohort trial of
SRS ± WBRT (12/53 (22.6%) received WBRT) compared against 67 WBRT historic control patients treated
1–3 years previously at the same institution for brain
metastases patients with multiple histologies and \4
tumors each \30 cc in volume. Groups were similar in
terms of sex and age, but differed in terms of lung and
breast cancer histology (67.9 vs. 83.6%). Number of brain
tumors, extent of extracranial disease, and baseline performance status were not reported. WBRT and SRS doses
were standard. They reported similar median survival of
only 6 months for both groups.
Stereotactic radiosurgery plus WBRT versus resection
plus WBRT
No prospective studies were identified that met the eligibility criteria for this treatment comparison. There were
four retrospective cohort studies (class II evidence) that
evaluated SRS ? WBRT vs. resection ? WBRT for the
initial management of patients with solid metastatic brain
tumors (Table 1) [53–56]. In all four of these unique studies, only single-dose SRS was evaluated, and the results
cannot be assumed to apply to 2–5 dose SRS [28, 29].
Bindal et al. [53] performed a retrospective cohort trial
of 62 patients with single brain metastases \3 cm in
diameter treated with resection ± WBRT matched for sex,
age, histology, KPS, and extent of disease to 31 patients
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undergoing SRS ± WBRT. WBRT was used in 66% of
patients in the first arm and 71% of patients in the second.
WBRT and SRS doses were standard. In this study,
resection ? WBRT achieved significantly longer median
survival (16.4 vs. 7.5 months) and median time to recurrence, as well as significantly lower rates of neurologic
death (19 vs. 50%) and adverse event rates than
SRS ? WBRT. This study reported significantly lower
median survival rates (only 7.5 months), as well as higher
radiation necrosis rates (12.9%), than have ever been
reported by other studies evaluating single brain metastases
treated with SRS ? WBRT. Given the poor compliance
with completion of WBRT in both arms, this study warrants retrospective down-grading to a class III evidence
level, a study with flawed internal validity.
In contrast, Garell et al., (1999) (1–2 tumors each
\3 cm diameter, n = 45), O’Neill et al., (2003) (single
tumors \3.5 cm, n = 97), and Schoggl et al., (2000)
(single tumors \3 cm diameter, n = 133) each reported
retrospective cohort studies of patients with brain metastases with very different results [54–56]. Median survival
was not significantly different but favored SRS ? WBRT
in two (12.5 vs. 8 months and 12 vs. 9 months, respectively) [54, 56], while 1 year survival was not significantly
different but slightly favored resection ? WBRT (62 vs.
56%) in the third [55]. Median time to recurrence, incidence of neurologic death, and incidence of acute and long
term adverse events were similar in both arms for the Mayo
Clinic study [55]. Median time to local recurrence was
significantly shorter (3.9 vs. 4.9 months) and the incidence
of neurologic death was greater (21.8 vs. 12.5%) in the
resection ? WBRT arm in the University of Vienna study,
while adverse event rates were similar [56]. Cause of death
and adverse event rates were not reported for the University of Iowa study [54], median time to recurrence was not
reported in either the University of Iowa or the Mayo
Clinic Studies [54, 55], and functional performance results
were not reported in any of the three [54–56].
Stereotactic radiosurgery alone versus resection plus
WBRT
One prospective RCT (class I evidence) [57], and two
retrospective cohort studies (class II evidence) evaluated
SRS alone vs. resection ? WBRT for the initial management of patients with solid metastatic brain tumors
(Table 1) [58, 59]. One retrospective cohort study (class II
evidence) evaluated SRS alone vs. resection ? WBRT or
local RT for the initial management of patients with solid
metastatic brain tumors (Table 1) [60]. These four unique
studies only evaluated single-dose SRS, and the results
cannot be assumed to apply to 2–5 dose SRS [28, 29].
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Muacevic et al., (2008) performed a multicenter prospective RCT evaluating patients with single metastatic
brain tumors, B3 cm diameter located in an operable site,
treated with either SRS alone (n = 31) or resection ?
WBRT (n = 33) [57]. Groups were similar in terms of sex,
age, histology, extent of systemic disease, and KPS score.
WBRT and SRS doses were standard. There was no significant difference in outcome between the two groups in
terms of functional performance outcome, rate of neurological death, or median survival (9.5 months surgery ? WBRT vs. 10.3 months SRS). However, the study
was stopped early at only 25% accrual and was therefore
underpowered to detect \15% differences in outcome
between groups. The SRS patients did experience an
increased number of distant tumor recurrences (25.8 vs.
3%), but these occurrences did not impact overall outcome
when subsequent salvage SRS was taken into account. The
resection ? WBRT group did experience a significantly
larger number of grade 1 or 2 early and late complications
compared with the SRS group.
Rades et al. [59] performed a retrospective cohort study
of SRS alone (n = 94) vs. resection ? WBRT (n = 112),
for RPA class I or II patients with metastatic brain tumors
B4 cm in diameter. Groups were similar in terms of sex,
age, histology, number of brain tumors, extent of systemic
disease, and KPS score. WBRT and SRS doses were
standard. Despite a trend favoring SRS alone, there was no
significant difference in outcome between groups for
1 year survival (54 vs. 38%). There was no significant
difference in outcomes for 1 year local recurrence rate (36
vs. 44%) or incidence of adverse events. Functional performance and neurologic cause of death outcomes were not
reported.
Muacevic et al., (1999) performed a retrospective cohort
study of SRS alone (n = 56) vs. resection ? WBRT
(n = 52), for patients with single metastatic brain tumors
B3.5 cm in diameter and with stable systemic disease
[58].Groups were similar in terms of sex, age, extent of
systemic disease, and KPS score. The SRS alone group had
a slightly higher proportion of patients with melanoma
(28.6 vs. 13.5%). WBRT and SRS doses were standard.
Despite a trend favoring resection ? WBRT, there was no
significant difference in outcome between groups for
median survival (35 vs. 68 weeks). There was no significant difference in outcomes for 1 year local recurrence rate
(17 vs. 25%), median time to recurrence, functional performance score, or incidence of adverse events.
Shinoura et al., (2002) performed a retrospective cohort
study of SRS alone (n = 52) vs. resection ? either WBRT
or local RT (n = 46, WBRT vs. local RT ratios not
reported) for patients with one or more metastatic brain
tumors \3 cm in diameter [60]. Groups were similar in
terms of sex, age and histology, but the SRS alone group
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had more patients with multiple tumors (77 vs. 37%).
Extent of extracranial disease and functional status were
not reported. WBRT, local RT, and SRS doses were standard. They reported significantly longer median survival
rates (34.4 vs. 8.2 months) as well as longer mean time to
recurrence rates (25 vs. 7.2 months) for the resection ? RT
arm. Cause of death and incidence of adverse events were
not reported.
Other comparisons
While our study group was interested in evaluating many
more treatment comparisons (including the effectiveness of
surgery plus SRS vs. resection plus WBRT, the effectiveness of substituting 2–5 dose SRS or fractionated stereotactic radiotherapy (6–9 dose) for single dose SRS, and the
effectiveness of substituting local fractionated radiotherapy
for WBRT) in various paradigm combinations, none of
these comparisons yielded more than one clinical study for
analysis, and some none at all. As a result, few conclusions
can be drawn at an evidence-based medicine clinical
practice parameter guideline level. Those few studies
where evidence exists are presented here for completeness
and interest sake and will be discussed further below in the
section on ‘‘Key Issues for Further Investigation’’.
Resection plus whole brain radiotherapy versus
resection plus stereotactic radiosurgery
No prospective studies were identified that met the eligibility criteria for this treatment comparison. There was one
retrospective cohort study (class II evidence) that evaluated
resection ? WBRT or local RT vs. SRS alone for the
initial management of patients with solid metastatic brain
tumors (Table 1) [61]. In this study, only single-dose SRS
was evaluated, and the results cannot be assumed to apply
to 2–5 dose SRS [28, 29].
Serizawa et al. [61] performed a retrospective cohort
study of resection ? WBRT (n = 34) vs. resection ? SRS
(n = 62) for NSCLC patients with multiple brain metastases B3 cm in diameter in patients estimated to have at
least 2 months to live. Groups were similar in terms of sex,
age, number of brain tumors, extent of systemic disease,
and KPS score. WBRT and SRS doses were standard. The
resection ? SRS alone group had significantly longer
median survival (377 vs. 199 days). Unfortunately this
result is difficult to evaluate given that the number of
patients in the resection ? WBRT arm that had resection
of all tumors vs. resection of only some of the 1–10 tumors
per patient were not defined. The resection ? SRS arm
also showed significantly longer neurological survival
rates. Local tumor control rates were not reported.
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Single-dose stereotactic radiosurgery versus multi-dose
stereotactic radiosurgery plus whole brain radiotherapy
No prospective studies were identified that met the eligibility criteria for this treatment comparison. There was one
retrospective cohort study (class II evidence) that evaluated
single-dose SRS alone vs. multi-dose SRS ? WBRT for
the initial management of patients with solid metastatic
brain tumors (Table 1) [62].
De Salles et al. [62] performed a retrospective cohort
study of SRS alone (n = 19) vs. WBRT ? multi-dose SRS
(n = 7) in patients with multiple histologies with one or
more metastatic brain tumors with volumes ranging from
0.09 to 51.84 cc (average volume 21.2 cc). Groups were
similar in terms of sex and age, but the SRS alone arm had
more melanoma patients (16 vs. 0%) and had significantly
more multiple brain tumor patients (34 tumors in 19
patients vs. seven tumors in seven patients). WBRT and
single-dose SRS doses were standard. The multi-dose SRS
regimen was 6 Gy per dose given in 2–3 doses over 2–3
days. There was no significant difference in average survival between both arms (8 vs. 7 months); however, this
study was underpowered to detect all but a very large
difference.

Multi-dose stereotactic radiosurgery versus whole brain
radiotherapy plus either single- or multi-dose SRS
No prospective studies were identified that met the eligibility criteria for this treatment comparison. There was one
retrospective cohort study with historical controls (class III
evidence) that evaluated multi-dose SRS vs. WBRT for the
initial management of patients with solid metastatic brain
tumors (Table 1) [63].
Lindvall et al. [63] performed a retrospective cohort
study of multi-dose SRS alone vs. WBRT ? either singleor multi-dose SRS in patients with 1–3 brain metastases of
varying histologies ranging in volume from 0.9 to 41 cc
(median volume 5 cc). Groups were similar in terms of sex,
extent of systemic disease, and KPS score. The multi-dose
SRS arm had younger patients (61.7% C 60 vs.
85.7% C 60), fewer melanoma patients (4.3 vs. 21.4%),
fewer RPA class I patients (4.3 vs. 21.4%) and more
patients with multiple brain tumors (23.4 vs. 14.2%). The
WBRT dose was standard. The multi-dose SRS regimen
was 40 Gy in five 8 Gy doses. The single- or multi-dose
boost regimen after WBRT was given in 1–3 doses of
6–12 Gy (mean total dose 17 Gy). There was no significant
difference in outcomes between groups for median survival
(5 vs. 5 months) or local progression (16 vs. 0%). There
was a significantly larger distant recurrence rate for the
multi-dose SRS alone arm (25 vs. 0%).

123

J Neurooncol (2010) 96:45–68

Fractionated stereotactic radiotherapy alone versus
resection with either whole brain radiotherapy or local
radiotherapy versus whole brain radiotherapy or local
radiotherapy alone
No prospective studies were identified that met the eligibility criteria for this treatment comparison. There was one
retrospective cohort study (class II evidence) that evaluated
fractionated stereotactic radiotherapy (FSR) alone vs.
resection plus WBRT or local RT vs. WBRT or local RT
alone, for the initial management of patients with solid
metastatic brain tumors (Table 1) [64].
Ikushima et al. [64] performed a three arm retrospective
cohort study in patients with 1–3 renal cell carcinoma brain
metastases each B3 cm in diameter in adult patients with an
Eastern Cooperative Oncology Group (ECOG) performance status of B2, comparing FSR (n = 10) vs. resection ? either WBRT or local RT vs. WBRT or local RT
alone. Patients were similar in terms of sex, age, and extent
of extracranial disease. The FSR alone arm had more
patients with single brain tumors, and the WBRT or local
RT alone arm had less patients with multiple brain tumors
than the resection ? either WBRT or local RT arm (90 vs.
70% and 50 vs. 36%, respectively). The WBRT or local RT
alone arm had more ECOG performance status two patients
than either the resection ? either WBRT or local RT, or the
FSR alone arm (50 vs. 18 vs. 0%). The WBRT and local RT
doses were standard. The FSR regimen was 42 Gy in seven
fractions (6 Gy per fraction) over 2.3 weeks. While 1 year
tumor control rates where similar for the FSR alone and the
resection ? either WBRT or local RT arms (89.6 vs.
87.5%), the FSR group had a significantly longer median
survival (25.6 months) than either the surgery ? either
WBRT or local RT (18.7 months), or the WBRT or local
RT alone arms (4.3 months).

Summary and discussion
Whole brain radiotherapy alone versus whole brain
radiotherapy plus stereotactic radiosurgery
There is class I evidence from two RCTs with similar
inclusion criteria that single-dose SRS ? WBRT provides
significantly superior local tumor control compared with
WBRT alone for patients with 1–3 brain metastases [25,
33] and evidence from one of the RCTs that this applies in
patients with up to four brain tumors [25]. One of the RCTs
also showed improved KPS score results for the singledose SRS ? WBRT regimen [33]. These results were
achieved without an increased incidence of adverse therapeutic events [33]. While local control was a secondary
endpoint, assessed post hoc in one of the RCTs [33], it was
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the primary endpoint in the second [25], which confirmed
the conclusion. Based on the inclusion criteria for
both RCTs, a level 1 recommendation for single-dose
SRS ? WBRT would only have external validity for
patients with a KPS C 70.
There is class I evidence from one RCT that single-dose
SRS ? WBRT provides a significantly superior survival
benefit compared with WBRT alone for patients with single brain metastases [33]. Once again, a level 1 recommendation reflecting a survival advantage in this setting for
single-dose SRS ? WBRT would only have external
validity for patients with a KPS C 70.
Whether or not a survival advantage might also exist for
patients with C2 brain metastases remains controversial.
Local tumor control is often assumed to dictate survival in
a disease where 50% of patients die a neurological death
with WBRT alone. It can be argued that one of the two
RCTs was affected by excessive bilateral cross over
(especially in the 2–3 tumor patient group) confounding the
intent-to-treat survival analysis for patients with 2–3
tumors, while the second RCT, using local control as the
primary endpoint, was stopped at too low a power to statistically prove a survival advantage in patients with 1–4
brain metastases. Certainly, the one class II evidence study
that includes patients with 1–6 metastases [36] as well as
the single class III evidence study [34] consistently support
a significant survival advantage for single-dose SRS ?
WBRT in patients with multiple metastatic brain tumors.
Nevertheless, a survival advantage for patients with 2–4
tumors has yet to be proven at the class I evidence level,
and at most a qualified level 2 recommendation can be
supported.
One class II study [36] and one class III study [34], each
found a survival advantage for SRS ? WBRT vs. WBRT
alone for patients with a KPS \ 70, irrespective of brain
tumor number, so long as all tumors were treated. The four
arm retrospective cohort study by Wang et al. [36] included patients with 1–6 brain metastases and KPS scores of
40–90. Unfortunately the KPS score distributions were not
stratified by treatment group for comparison purposes. The
Sanghavi et al. [37] retrospective cohort study compared
against the RTOG database and stratified by RPA classification is a much better designed study, but only rises to
the class III evidence level. At most, the evidence supports
a qualified level 3 recommendation regarding a survival
advantage for SRS ? WBRT over WBRT alone for
patients with a KPS \ 70.
Stereotactic radiosurgery alone versus whole brain
radiotherapy plus stereotactic radiosurgery
One RCT [38], one prospective cohort study (class II evidence) [35], and eight of 10 retrospective cohort studies

63

(class II evidence) [40, 42–48] support equivalent survival
results for single-dose SRS alone vs. WBRT ? single-dose
SRS, and one study restricted to breast cancer suggested a
survival advantage for the single-dose SRS alone strategy
[41]. Only one retrospective cohort study showed a survival result favoring WBRT ? single-dose SRS, and this
study was unusual in that it only included patients who had
already survived [1 year since initial treatment [48].
Regarding local recurrence risk, the RCT [38] as well as
1/10 retrospective cohort studies [48] demonstrated that a
single-dose SRS alone strategy led to a higher risk of local
recurrence at the treated site compared with WBRT ?
single-dose SRS. A third study (second retrospective
cohort study) reported an increased 1 year local recurrence
rate (22 vs. 6%) but did not report statistical analysis [44].
In contrast, the prospective cohort study [35] as well as 6/
10 retrospective cohort studies [36, 41–43, 45, 46] showed
no significant difference in local recurrence risk at the
treated site between the two treatment strategies. Clearly
there exists conflicting data regarding the risk of local
recurrence at the treated site if single-dose SRS is utilized
in isolation. This conflicting evidence suggests that further
study may be needed to define optimal dose prescription
and/or dose rate for isolated SRS as opposed to SRS performed in the setting of an additive WBRT dose.
Three class I studies have demonstrated that WBRT
lowers the risk of distant recurrence compared to local
tumor therapies (SRS or surgical resection) used in isolation [15, 38, 57]. There is, however, disagreement among
class I and II studies regarding the risk of distant recurrence
outside the treatment volume if single-dose SRS is used in
isolation as opposed to WBRT ? single-dose SRS. The
RCT [38], as well as 4/10 retrospective cohort studies [40,
42, 44, 45], demonstrated a significantly increased risk of
either distant brain or overall brain recurrence when singledose SRS is utilized in isolation and no advantage to SRS
alone when assessing neurocognitive sequelae from radiation. The prospective cohort study [35] as well as 2/10
retrospective cohort studies [36, 47] did not assess the
distant recurrence rate. Four of 10 retrospective cohort
studies, however, revealed no significant difference in the
distant recurrence rate between the two treatment strategies
[41, 43, 46, 48]. Given the above results, prudence warrants
regular careful surveillance at 2–3 month intervals with
neuro-imaging if single-dose SRS is utilized in isolation.
An area that has not been fully studied to date includes
the potential neuropsychological effects of adding WBRT
to a SRS treatment regimen vs. the potential adverse neurocognitive effects of a potentially greater risk of recurrence outside the SRS site. Assessing functional status
outcomes using standard functional scores tends to be
insensitive to subtle neurocognitive effects. Even the
MMSE is likely to be too crude a measure to assess the
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neurocognitive parameters of interest to physicians and
patients. Thus, a careful surveillance imaging strategy, if
SRS is utilized in isolation, should be validated for both
efficacy and for preserving neurocognitive function. While
outside the specific search criteria for this chapter, limited
evidence to date suggests that tumor recurrence is also
associated with neurocognitive decline and thus may be
taken into consideration when deciding to forego up-front
WBRT. The potential differential neurocognitive consequences between these two therapeutic choices (SRS alone
vs. SRS ? WBRT) have not been well studied and remain
uncertain, even if a careful surveillance strategy is implemented when SRS is used in isolation.
Stereotactic radiosurgery alone versus whole brain
radiotherapy alone
The four class II evidence studies evaluating this comparison all demonstrated a statistically significant survival
advantage for single-dose SRS alone compared with
WBRT alone for patients with either single or multiple
brain tumors [35, 36, 49, 50]. However, one study was
confounded by the inclusion of SCLC patients who are
normally excluded from solid metastatic brain tumor
analysis, particularly in a study in which WBRT is not
included in one of the arms [35]. A second study included a
very small number of patients and was limited by selective
rare histology (epithelial ovarian cancer only), and poor
intergroup comparative analysis [49]. Consistent with these
results, one class III evidence study showed a significant
survival advantage for single-dose SRS alone for RPA
class I and II, but not RPA class III patients [52]. Only one
class III evidence study showed similar survival results for
both treatment strategies [51]. While different studies
evaluated patients with differing numbers of brain metastases, all studies included patients with up to three metastatic brain tumors. Given the relative paucity and
weakness of the data, and despite relatively consistent
results, only a level 3 recommendation is warranted.
Stereotactic radiosurgery plus WBRT versus resection
plus WBRT
Of the four retrospective cohort trials evaluating this
comparison, three demonstrated no significant survival
differences between the two strategies [54–56]. Of these,
two showed a trend favoring single-dose SRS ? WBRT
[54, 56] and one a trend favoring resection ? WBRT [55].
Only one of the studies demonstrated a significant survival
advantage for resection ? WBRT [51]. This study reported
SRS ? WBRT results far worse than those reported by
most studies using this strategy, both in terms of per
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survival results as well as excessive therapeutic toxicity
and had poor enough internal validity that our writing
group favored down-grading it from class II to class III
evidence [53]. As further outlined and discussed in the
surgical resection practice guideline of this series for brain
metastases, these results suggest equivalence in survival
results and a level 2 recommendation is consistent between
the two guideline papers.
Stereotactic radiosurgery alone versus resection plus
WBRT
One class I evidence study evaluating this comparison
revealed no significant difference in functional performance outcome, neurological death outcome or median
survival for patients with single brain metastases [57].
However, this study was closed prematurely with only 25%
patient accrual for a study originally designed to detect a
15% difference in survival between the two groups. The
revised statistical power calculation based on actual accrual
data was designed to detect a survival difference of 38% or
more in favor of surgery with 80% power (in accordance
with a scenario retrospectively described by Bindal et al. in
1996). The actual sample size was large enough to reject
the Bindal hypothesis concerning the overwhelming impact
of surgery and in fact, revealed no significant difference
between the two groups.
Of the three class II evidence studies evaluating this
comparison, two revealed no significant difference in
median survival for patients with 1–3 brain metastases [59,
60]. One suggested a trend favoring single-dose SRS alone
for patients with 1–3 tumors [59], while the other suggested
a trend favoring resection ? WBRT for patients with single metastatic tumors [60]. The third study demonstrating a
significant survival advantage for resection ? WBRT or
local RT was confounded by poor comparability among
patient treatment arms with the SRS alone arm containing
more than twice the percentage of multiple metastatic brain
tumor patients than the resection ? RT arm [60].
While the result for this comparison is one of the most
eagerly anticipated in neuro-oncology, the current power
flaws for the only class I evidence study, as well as the
relative paucity, weakness, and conflicting results among
other published evidence at most supports a level 3 recommendation for SRS in lieu of resection ? WBRT.
Other comparisons
The absent and/or severely limited evidence (number as
well as quality of studies) so far published in peer review
literature does not yet support any clinical practice
parameter guideline recommendations regarding:
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1.

2.

3.

The effectiveness of resection ? single-dose SRS vs.
resection ? WBRT for patients with one or more solid
brain metastases.
The effectiveness of substituting 2–5 dose SRS, or
even 6–9 dose FSR, for single-dose SRS evaluated in
the comparisons above and reflected in the clinical
practice parameter guideline recommendations.
The effectiveness of substituting local RT for WBRT
in the comparisons above and reflected in the clinical
practice parameter guideline recommendations.

Key issues for further investigation
1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

The potential survival advantage of single-dose
SRS ? WBRT for patients with C2 metastatic brain
tumors \3 cm in diameter remains controversial and
warrants further investigation with a RCT designed
for sufficient statistical power for these patients with
median survival as the primary endpoint.
The potential survival advantage of single-dose SRS ?
WBRT for patients with a KPS \ 70 warrants further
investigation in the form of a RCT.
The local control advantage of single-dose SRS for
patients with C4 metastatic brain tumors and a KPS C
70 warrants further investigation in the form of a RCT.
The optimal dose and/or dose rate for single-dose
SRS utilized in isolation for treating metastatic brain
tumors in order to ensure equivalent local recurrence
rates compared with current single dose SRS ?
WBRT doses warrants further study.
The neurocognitive effects of SRS alone with careful
neuroimaging follow-up leading to potential salvage
SRS if recurrence develops, vs. SRS ? WBRT,
warrants further study with appropriate validated
neurocognitive instruments and endpoints.
Based on current evidence classifications, single-dose
SRS ? WBRT vs. resection ? WBRT warrants
investigation in the form of a RCT.
Single-dose SRS alone vs. resection ? WBRT warrants further investigation in the form of either a
prospective cohort study or a RCT.
Resection ? single-dose SRS vs. resection ? WBRT
warrants further investigation in the form of either a
prospective cohort study or a RCT.
2–5 dose SRS is relatively unproven in any of the
comparison paradigms discussed in this paper. Clinical trials of 2–3 dose SRS vs. single-dose SRS are
needed for all treatment comparisons outlined in this
paper in either the form of prospective cohort studies
or RCTs.
The effectiveness of local RT is relatively unproven
compared with WBRT in any of the comparison
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paradigms discussed in this paper. Clinical trials of
local RT vs. WBRT are most needed for settings
of limited CNS disease where treatment strategies
are designed to maximize local control (e.g., SRS ?
local RT vs. SRS ? WBRT or resection ? local RT
vs. resection ? WBRT).
The following is a list of major ongoing randomized trials
pertaining to the use of stereotactic radiosurgery that
evaluate treatment comparisons addressed by this guideline
paper for the management of newly diagnosed brain
metastases.
1.

2.

Randomized trial comparing radiosurgery with vs
without whole brain radiotherapy
Official title: A phase III prospective randomized trial
comparing radiosurgery with versus without whole
brain radiotherapy for 1–3 newly diagnosed brain
metastases
Status: Active, not recruiting (Phase III)
Clinicaltrials.gov Identifier: NCT00548756
Principal Investigator: Eric L. Chang, MD, U.T.M.D.
Anderson Cancer Center
Location: United States
Sponsors and Collaborators: M.D. Anderson Cancer
Center
Stereotactic radiation therapy with or without wholebrain radiation therapy in treating patients with brain
metastases
Official title: Phase III randomized trial of the role of
whole brain radiation therapy in addition to radiosurgery in patients with one to three cerebral metastases
Status: Recruiting (Phase III)
Clinicaltrials.gov Identifier: NCT00377156
Principal Investigators:
Study Chair: Paul D. Brown, MD Mayo Clinic
Investigator: Kurt A. Jaeckle, MD Mayo Clinic
Investigator: Richard L. Deming, MD Mercy Therapeutic Radiology Associates, PC at Mercy Medical
Center - Des Moines
Investigator: Elana Farace, PhD Milton S. Hershey
Medical Center
Investigator: Bruce Pollock, MD Mayo Clinic
Study Chair: Anthony Asher, MD, FACS Carolina
Neurosurgery and Spine Associates
Investigator: Fred G. Barker, MD Massachusetts
General Hospital
Study Chair: Larry Kleinberg, MD Sidney Kimmel
Comprehensive Cancer Center
Study Chair: Anthony Asher, MD, FACS Carolina
Neurosurgery and Spine Associates
Location: United States and Canada (38 locations)
Sponsors and Collaborators:
North Central Cancer Treatment Group
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3.

4.

5.

6.
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National Cancer Institute (NCI)
American College of Surgeons
Eastern Cooperative Oncology Group
Radiation Therapy Oncology Group
Surgery versus stereotactic radiosurgery in the treatment of single brain metastasis: a randomized trial
Official title: Surgery versus stereotactic radiosurgery
in the treatment of single brain metastasis: a randomized trial
Status: Completed
Clinicaltrials.gov Identifier: NCT00460395
Principal Investigator: Frederick F. Lang, M.D.,
University Of Texas MD Anderson Cancer Center
Location: United States
Sponsors and Collaborators: M.D. Anderson Cancer
Center
Surgery versus radiosurgery to treat metastatic brain
tumors
Official title: A prospective, randomized trial comparing surgery versus radiosurgery for the treatment of
metastatic brain tumors
Status: Completed
Clinicaltrials.gov Identifier: NCT00075166
Location: United States
Sponsors and Collaborators: National Institute of
Neurological Disorders and Stroke (NINDS)
A trial of postoperative whole brain radiation therapy vs.
salvage stereotactic radiosurgery therapy for metastasis
Official title: Randomized phase III trial of postoperative whole brain radiation therapy compared with
salvage stereotactic radiosurgery in patients with one to
four brain metastasis: Japan Clinical Oncology Group
Study (JCOG 0504)
Status: Recruiting (Phase III)
Clinicaltrials.gov Identifier: NCT00280475
Principal Investigator: Takamasa Kayama, MD, PhD
Yamagata University Faculty of Medicine
Location: Japan (21 locations)
Sponsors and Collaborators:
Japan Clinical Oncology Group
Japanese Ministry of Health, Labor and Welfare
A trial comparing radiosurgery with surgery for
solitary brain metastases
Official title: A randomised trial of surgery plus whole
brain radiotherapy (WBRT) versus radiosurgery plus
WBRT for solitary brain metastases
Status: Recruiting (Phase III)
Clinicaltrials.gov Identifier: NCT00124761
Principal Investigator: Daniel Roos, FRANZCR,
Royal Adelaide Hospital
Location: Australia
Sponsors and Collaborators: Royal Adelaide
Hospital
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7.

Adjuvant radiation therapy in treating patients with
brain metastases
Official title: Phase III trial on convergent beam
irradiation of cerebral metastases
Status: Active, not recruiting (Phase III)
Clinicaltrials.gov Identifier: NCT00002899
Principal Investigators:
Rolf-Peter Mueller, MD Medizinische Universitaetsklinik I at the University of Cologne
Riccardo Soffietti, MD Universita Degli Studi di Turin
Location: Europe (33 locations)
Sponsors and Collaborators: European Organization
for Research and Treatment of Cancer
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